Journal of Medicinal Chemistry · 2015 · 58 citations · 48 references
PharmacyOncologyPharmacologyDrug DesignDrug DiscoveryLead OptimizationHit-to-lead OptimizationLead Compound DesignLead DiscoveryLung Cancer PharmacotherapyPotency OptimizationEgfr InhibitionEpidermal Growth Factor Receptor InhibitionKinase InhibitorsMutationNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentStructure-guided DesignStructure-guided Lead Discovery
Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clinical responses only last for 8-14 months. Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel). Herein we describe how a noncovalent double mutant selective lead compound was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or reduction of three-dimensional character. Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom. Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.
48
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +15